📊 TNDM Key Takeaways
Is Tandem Diabetes Care Inc. (TNDM) a Good Investment?
TNDM is in a deepening profitability crisis with net losses deteriorating 113% YoY while generating negative operating cash flow and burning $29.7M in free cash flow. The $310M debt load is unsustainable given negative interest coverage, leaving only ~3 years of cash runway at current burn rates. While gross margins of 53.8% demonstrate product viability, operating expenses are spiraling out of control faster than the 7.9% revenue growth can offset.
Why Buy Tandem Diabetes Care Inc. Stock? TNDM Key Strengths
- Healthy gross margin of 53.8% indicating strong product positioning and pricing power in diabetes care market
- Solid short-term liquidity with 2.55x current ratio providing near-term operational flexibility
- Continued 7.9% YoY revenue growth demonstrates market demand for core products
TNDM Stock Risks: Tandem Diabetes Care Inc. Investment Risks
- Accelerating losses with net income deteriorating 113.2% YoY, indicating worsening operational efficiency
- Negative free cash flow of -$29.7M and operating cash burn of -$9.7M makes business model unsustainable without capital injection
- 2.0x debt-to-equity ratio with negative interest coverage due to -$187.3M operating loss creates debt service crisis
- Cash runway of ~3 years at current burn rate with no clear path to profitability
- Operating margin of -18.5% with losses accelerating despite revenue growth signals structural cost control failure
Key Metrics to Watch
- Operating cash flow and free cash flow inflection to positive within 2-3 quarters
- Operating margin trend and path to break-even or positive territory
- Cash balance and burn rate sustainability against debt obligations and liquidity needs
Tandem Diabetes Care Inc. (TNDM) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.55x current ratio provides a solid financial cushion.
TNDM Profit Margin, ROE & Profitability Analysis
TNDM vs Healthcare Sector: How Tandem Diabetes Care Inc. Compares
How Tandem Diabetes Care Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tandem Diabetes Care Inc. Stock Overvalued? TNDM Valuation Analysis 2026
Based on fundamental analysis, Tandem Diabetes Care Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tandem Diabetes Care Inc. Balance Sheet: TNDM Debt, Cash & Liquidity
TNDM Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tandem Diabetes Care Inc.'s revenue has grown significantly by 44% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.43 indicates the company is currently unprofitable.
TNDM Revenue Growth, EPS Growth & YoY Performance
TNDM Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $244.0M | -$21.2M | $-0.31 |
| Q2 2025 | $221.9M | -$30.8M | $-0.47 |
| Q1 2025 | $191.7M | -$42.7M | $-0.65 |
| Q3 2024 | $185.6M | -$23.3M | $-0.35 |
| Q2 2024 | $195.9M | -$30.8M | $-0.47 |
| Q1 2024 | $169.4M | -$42.7M | $-0.65 |
| Q3 2023 | $185.6M | -$33.0M | $-0.51 |
| Q2 2023 | $195.9M | -$15.1M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tandem Diabetes Care Inc. Dividends, Buybacks & Capital Allocation
TNDM SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tandem Diabetes Care Inc. (CIK: 0001438133)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TNDM
What is the AI rating for TNDM?
Tandem Diabetes Care Inc. (TNDM) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TNDM's key strengths?
Claude: Healthy gross margin of 53.8% indicating strong product positioning and pricing power in diabetes care market. Solid short-term liquidity with 2.55x current ratio providing near-term operational flexibility.
What are the risks of investing in TNDM?
Claude: Accelerating losses with net income deteriorating 113.2% YoY, indicating worsening operational efficiency. Negative free cash flow of -$29.7M and operating cash burn of -$9.7M makes business model unsustainable without capital injection.
What is TNDM's revenue and growth?
Tandem Diabetes Care Inc. reported revenue of $1.0B.
Does TNDM pay dividends?
Tandem Diabetes Care Inc. does not currently pay dividends.
Where can I find TNDM SEC filings?
Official SEC filings for Tandem Diabetes Care Inc. (CIK: 0001438133) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TNDM's EPS?
Tandem Diabetes Care Inc. has a diluted EPS of $-3.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TNDM a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Tandem Diabetes Care Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TNDM stock overvalued or undervalued?
Valuation metrics for TNDM: ROE of -131.9% (sector avg: 15%), net margin of -20.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TNDM stock in 2026?
Our dual AI analysis gives Tandem Diabetes Care Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TNDM's free cash flow?
Tandem Diabetes Care Inc.'s operating cash flow is $-9.7M, with capital expenditures of $19.9M. FCF margin is -2.9%.
How does TNDM compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -20.2% (avg: 12%), ROE -131.9% (avg: 15%), current ratio 2.55 (avg: 2).
Is Tandem Diabetes Care Inc. carrying too much debt?
TNDM has a debt-to-equity ratio of 2.00x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 2.55 suggests adequate short-term liquidity.